Annabel Jane Sharkey
Research Subjects
Research Interests
Annabel Jane Sharkey has a total of 109 co-authors. Here are the top co-authors by number of shared publications:
- Sara Busacca
Leicester Cancer Research Centre, University of Leicester, Leicester, United Kingdom
31 shared publications Apostolos Nakas
28 shared publicationsDean A. Fennell
28 shared publications- Aaron Scott Mansfield
Mayo Clinic
23 shared publications - Aimee Parsons
Leicester Cancer Research Centre, University of Leicester, Leicester, United Kingdom
23 shared publications Alan G. Dawson
23 shared publications
Latest Publications
- Open Access
- 3 April 2023
- Published by American Association for Cancer Research (AACR)
Data from BRCA1/MAD2L1 Deficiency Disrupts the Spindle Assembly Checkpoint to Confer Vinorelbine Resistance in Mesothelioma
Mesothelioma is a universally lethal cancer lacking effective therapy. The spindle poison vinorelbine exhibits clinical activity in the relapsed setting, and in preclinical models requires BRCA1 to initiate apoptosis. However, the mechanisms underlying this regulation and the clinical implications have not been explored. Here, we show that BRCA1 silencing abrogated vinorelbine-induced cell-cycle arrest, recruitment of BUBR1 to kinetochores, and apoptosis. BRCA1 silencing led to codepletion of MAD2L1 at the mRNA and protein levels consistent with its status as a transcriptional target of BRCA1. Silencing of MAD2L1 phenocopied BRCA1 and was sufficient to confer resistance to vinorelbine. This was recapitulated in cell lines selected for resistance to vinorelbine, which acquired loss of both BRCA1 and MAD2L1 expression. Following ex vivo vinorelbine in 20 primary tumor explants, apoptotic response rate was 59% in BRCA1/MAD2L1-positive explants compared with 0% in BRCA1/MAD2L1-negative explants. In 48 patients, BRCA1 and/or MAD2L1 loss of expression was not prognostic; however, in a subset of patients treated with vinorelbine, survival was shorter for patients lacking BRCA1/MAD2L1 expression compared with double-positive patients (5.9 vs. 36.7 months, P = 0.03). Our data implicate BRCA1/MAD2L1 loss as a putative predictive marker of resistance to vinorelbine in mesothelioma and warrant prospective clinical evaluation.
- 3 April 2023
- Published by American Association for Cancer Research (AACR)
Open AccessData from BRCA1/MAD2L1 Deficiency Disrupts the Spindle Assembly Checkpoint to Confer Vinorelbine Resistance in Mesothelioma
Mesothelioma is a universally lethal cancer lacking effective therapy. The spindle poison vinorelbine exhibits clinical activity in the relapsed setting, and in preclinical models requires BRCA1 to initiate apoptosis. However, the mechanisms underlying this regulation and the clinical implications have not been explored. Here, we show that BRCA1 silencing abrogated vinorelbine-induced cell-cycle arrest, recruitment of BUBR1 to kinetochores, and apoptosis. BRCA1 silencing led to codepletion of MAD2L1 at the mRNA and protein levels consistent with its status as a transcriptional target of BRCA1. Silencing of MAD2L1 phenocopied BRCA1 and was sufficient to confer resistance to vinorelbine. This was recapitulated in cell lines selected for resistance to vinorelbine, which acquired loss of both BRCA1 and MAD2L1 expression. Following ex vivo vinorelbine in 20 primary tumor explants, apoptotic response rate was 59% in BRCA1/MAD2L1-positive explants compared with 0% in BRCA1/MAD2L1-negative explants. In 48 patients, BRCA1 and/or MAD2L1 loss of expression was not prognostic; however, in a subset of patients treated with vinorelbine, survival was shorter for patients lacking BRCA1/MAD2L1 expression compared with double-positive patients (5.9 vs. 36.7 months, P = 0.03). Our data implicate BRCA1/MAD2L1 loss as a putative predictive marker of resistance to vinorelbine in mesothelioma and warrant prospective clinical evaluation.
- Open Access
- 3 April 2023
- Published by American Association for Cancer Research (AACR)
Data from BRCA1/MAD2L1 Deficiency Disrupts the Spindle Assembly Checkpoint to Confer Vinorelbine Resistance in Mesothelioma
Mesothelioma is a universally lethal cancer lacking effective therapy. The spindle poison vinorelbine exhibits clinical activity in the relapsed setting, and in preclinical models requires BRCA1 to initiate apoptosis. However, the mechanisms underlying this regulation and the clinical implications have not been explored. Here, we show that BRCA1 silencing abrogated vinorelbine-induced cell-cycle arrest, recruitment of BUBR1 to kinetochores, and apoptosis. BRCA1 silencing led to codepletion of MAD2L1 at the mRNA and protein levels consistent with its status as a transcriptional target of BRCA1. Silencing of MAD2L1 phenocopied BRCA1 and was sufficient to confer resistance to vinorelbine. This was recapitulated in cell lines selected for resistance to vinorelbine, which acquired loss of both BRCA1 and MAD2L1 expression. Following ex vivo vinorelbine in 20 primary tumor explants, apoptotic response rate was 59% in BRCA1/MAD2L1-positive explants compared with 0% in BRCA1/MAD2L1-negative explants. In 48 patients, BRCA1 and/or MAD2L1 loss of expression was not prognostic; however, in a subset of patients treated with vinorelbine, survival was shorter for patients lacking BRCA1/MAD2L1 expression compared with double-positive patients (5.9 vs. 36.7 months, P = 0.03). Our data implicate BRCA1/MAD2L1 loss as a putative predictive marker of resistance to vinorelbine in mesothelioma and warrant prospective clinical evaluation.
- 3 April 2023
- Published by American Association for Cancer Research (AACR)
Open AccessData from BRCA1/MAD2L1 Deficiency Disrupts the Spindle Assembly Checkpoint to Confer Vinorelbine Resistance in Mesothelioma
Mesothelioma is a universally lethal cancer lacking effective therapy. The spindle poison vinorelbine exhibits clinical activity in the relapsed setting, and in preclinical models requires BRCA1 to initiate apoptosis. However, the mechanisms underlying this regulation and the clinical implications have not been explored. Here, we show that BRCA1 silencing abrogated vinorelbine-induced cell-cycle arrest, recruitment of BUBR1 to kinetochores, and apoptosis. BRCA1 silencing led to codepletion of MAD2L1 at the mRNA and protein levels consistent with its status as a transcriptional target of BRCA1. Silencing of MAD2L1 phenocopied BRCA1 and was sufficient to confer resistance to vinorelbine. This was recapitulated in cell lines selected for resistance to vinorelbine, which acquired loss of both BRCA1 and MAD2L1 expression. Following ex vivo vinorelbine in 20 primary tumor explants, apoptotic response rate was 59% in BRCA1/MAD2L1-positive explants compared with 0% in BRCA1/MAD2L1-negative explants. In 48 patients, BRCA1 and/or MAD2L1 loss of expression was not prognostic; however, in a subset of patients treated with vinorelbine, survival was shorter for patients lacking BRCA1/MAD2L1 expression compared with double-positive patients (5.9 vs. 36.7 months, P = 0.03). Our data implicate BRCA1/MAD2L1 loss as a putative predictive marker of resistance to vinorelbine in mesothelioma and warrant prospective clinical evaluation.
- Open Access
- 3 April 2023
- Published by American Association for Cancer Research (AACR)
Figure S5 from BRCA1/MAD2L1 Deficiency Disrupts the Spindle Assembly Checkpoint to Confer Vinorelbine Resistance in Mesothelioma
Prognostic effect of MAD2L1 in second line cohort. Kaplan Meier curve for overall survival (OS) in patients treated with vinorelbine second line (n=3) stratified according to MAD2L1 expression
- 3 April 2023
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S5 from BRCA1/MAD2L1 Deficiency Disrupts the Spindle Assembly Checkpoint to Confer Vinorelbine Resistance in Mesothelioma
Prognostic effect of MAD2L1 in second line cohort. Kaplan Meier curve for overall survival (OS) in patients treated with vinorelbine second line (n=3) stratified according to MAD2L1 expression
- Open Access
- 3 April 2023
- Published by American Association for Cancer Research (AACR)
Figure S1 from BRCA1/MAD2L1 Deficiency Disrupts the Spindle Assembly Checkpoint to Confer Vinorelbine Resistance in Mesothelioma
BRCA2 is not required for vinorelbine-induced cell death MSTO and REN cells were transfected with siNT and siBRCA2. 24 hours following transfection, cells were treated with vinorelbine 100 nM for a further 48 hours and caspase 3 activity measured. Data were normalised to untreated siNT control. Western blots show downregulation of BRCA2 after silencing. MSTO-211H: siNT NT vs siNT VNB p<0.0001; siBRCA2 VNB vs siBRCA2 VNB p<0.0001. REN: siNT NT vs siNT VNB p<0.0001; siBRCA2 VNB vs siBRCA2 VNB p<0.0001.
- 3 April 2023
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S1 from BRCA1/MAD2L1 Deficiency Disrupts the Spindle Assembly Checkpoint to Confer Vinorelbine Resistance in Mesothelioma
BRCA2 is not required for vinorelbine-induced cell death MSTO and REN cells were transfected with siNT and siBRCA2. 24 hours following transfection, cells were treated with vinorelbine 100 nM for a further 48 hours and caspase 3 activity measured. Data were normalised to untreated siNT control. Western blots show downregulation of BRCA2 after silencing. MSTO-211H: siNT NT vs siNT VNB p<0.0001; siBRCA2 VNB vs siBRCA2 VNB p<0.0001. REN: siNT NT vs siNT VNB p<0.0001; siBRCA2 VNB vs siBRCA2 VNB p<0.0001.
- Open Access
- 3 April 2023
- Published by American Association for Cancer Research (AACR)
Figure S7 from BRCA1/MAD2L1 Deficiency Disrupts the Spindle Assembly Checkpoint to Confer Vinorelbine Resistance in Mesothelioma
Western blot images for replicates. Replicate images for figure 1, figure 2 and figure 3.
- 3 April 2023
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S7 from BRCA1/MAD2L1 Deficiency Disrupts the Spindle Assembly Checkpoint to Confer Vinorelbine Resistance in Mesothelioma
Western blot images for replicates. Replicate images for figure 1, figure 2 and figure 3.
- Open Access
- 3 April 2023
- Published by American Association for Cancer Research (AACR)
Figure S5 from BRCA1/MAD2L1 Deficiency Disrupts the Spindle Assembly Checkpoint to Confer Vinorelbine Resistance in Mesothelioma
Prognostic effect of MAD2L1 in second line cohort. Kaplan Meier curve for overall survival (OS) in patients treated with vinorelbine second line (n=3) stratified according to MAD2L1 expression
- 3 April 2023
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S5 from BRCA1/MAD2L1 Deficiency Disrupts the Spindle Assembly Checkpoint to Confer Vinorelbine Resistance in Mesothelioma
Prognostic effect of MAD2L1 in second line cohort. Kaplan Meier curve for overall survival (OS) in patients treated with vinorelbine second line (n=3) stratified according to MAD2L1 expression
- Open Access
- 3 April 2023
- Published by American Association for Cancer Research (AACR)
Figure S4 from BRCA1/MAD2L1 Deficiency Disrupts the Spindle Assembly Checkpoint to Confer Vinorelbine Resistance in Mesothelioma
Prognostic effect of BRCA1 and MAD2L1. Kaplan Meier curve for overall survival (OS) in patients (n=48) showing survival in patients who were negative for both BRCA1 and MAD2L1 compared to patients positive for either BRCA1 or MAD2L1 and in patients negative for both BRCA1 and MAD2L1 vs patients positive for both BRCA1 and MAD2L1 vs patients negative for either BRCA1 or MAD2L1
- 3 April 2023
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S4 from BRCA1/MAD2L1 Deficiency Disrupts the Spindle Assembly Checkpoint to Confer Vinorelbine Resistance in Mesothelioma
Prognostic effect of BRCA1 and MAD2L1. Kaplan Meier curve for overall survival (OS) in patients (n=48) showing survival in patients who were negative for both BRCA1 and MAD2L1 compared to patients positive for either BRCA1 or MAD2L1 and in patients negative for both BRCA1 and MAD2L1 vs patients positive for both BRCA1 and MAD2L1 vs patients negative for either BRCA1 or MAD2L1
- Open Access
- 3 April 2023
- Published by American Association for Cancer Research (AACR)
Figure S7 from BRCA1/MAD2L1 Deficiency Disrupts the Spindle Assembly Checkpoint to Confer Vinorelbine Resistance in Mesothelioma
Western blot images for replicates. Replicate images for figure 1, figure 2 and figure 3.
- 3 April 2023
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S7 from BRCA1/MAD2L1 Deficiency Disrupts the Spindle Assembly Checkpoint to Confer Vinorelbine Resistance in Mesothelioma
Western blot images for replicates. Replicate images for figure 1, figure 2 and figure 3.